Neogen (NEOG) to Report Q1 2025 Earnings with Expected EPS of $0.07
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 07 2026
0mins
Should l Buy NEOG?
Source: Benzinga
- Earnings Release: Neogen is set to release its Q1 2025 earnings on January 8, 2025, with an expected EPS of $0.07, down from $0.11 in the previous year, indicating potential profitability challenges for the company.
- Revenue Expectations: Analysts forecast Neogen's quarterly revenue to be $208.38 million, a decline from $231.26 million a year earlier, suggesting weakening market demand could impact the company's performance.
- Executive Appointments: On January 5, Neogen announced the appointments of Joe Freels as Senior Vice President and Chief Commercial Officer and Dr. Tammi Ranalli as Senior Vice President and General Manager of Global Food Safety, aiming to strengthen its leadership to tackle market challenges.
- Stock Movement: Neogen's shares rose 2.1% to close at $7.41 on Tuesday, reflecting cautious optimism in the market despite the downward revision in earnings expectations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NEOG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NEOG
Wall Street analysts forecast NEOG stock price to fall
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 10.780
Low
6.50
Averages
8.17
High
10.00
Current: 10.780
Low
6.50
Averages
8.17
High
10.00
About NEOG
Neogen Corporation and subsidiaries are engaged in developing, manufacturing and marketing a diverse line of products and services dedicated to food and animal safety. The Company has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. Its segments include Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including a complete line of consumable products marketed to veterinarians and animal health product distributors. This segment also provides genomic identification and related interpretive bioinformatic services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Neogen Corporation Initiates Nationwide Recall of HYCOAT Product
- Product Recall: Neogen Corporation has initiated a voluntary recall of all unexpired lots of its HYCOAT Hyaluronate Sodium Sterile Solution due to identified microbial contamination in certain batches, impacting its use for topical wound management in dogs, cats, and horses.
- Adverse Event Reports: The company received several adverse event reports following intra-articular injections in horses, a use inconsistent with the product's labeling, although no adverse events were reported when used as directed, highlighting the risks associated with improper use.
- Infection Risk Warning: Neogen warned that affected products should no longer be considered sterile, posing an infection risk particularly if injected into joints or used topically in surgical wounds, burns, ulcers, and autograft procedures.
- Stock Price Reaction: According to Benzinga Pro data, NEOG stock fell 2.80% to $10.06 in the last check on Thursday, reflecting the market's negative response to the recall event.
See More
Neogen Voluntarily Recalls HYCOAT Product Due to Contamination
- Product Recall: Neogen Corporation is voluntarily recalling all lots of Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution due to microbial contamination in certain 10 mL/50 mg vials, which poses a risk of infection in animals and could damage the company's reputation.
- Adverse Event Reports: The company has received multiple reports of adverse events in horses following intraarticular injections, although no issues have been reported when used as intended, highlighting the risks associated with improper use of the product.
- Collaboration with FDA: Neogen is proactively working with the FDA to investigate the issue and is notifying distributors and customers to ensure a smooth recall process, aiming to mitigate potential legal and financial risks.
- Customer Support: The company is providing a customer support hotline to assist with recall procedures, demonstrating its commitment to customer safety, which may also impact future sales and market trust.
See More
Neogen Voluntarily Recalls HYCOAT Product Due to Contamination
- Product Recall: Neogen Corporation is voluntarily recalling all lots of Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution due to microbial contamination found in certain batches, involving both 2mL/20mg and 10mL/50mg vials, demonstrating the company's commitment to product safety.
- Adverse Event Reports: Following intraarticular injections in horses, Neogen received multiple reports of adverse events, although no issues were reported when used as intended, indicating potential serious consequences from improper use that could impact the company's reputation.
- Collaboration with FDA: Neogen is proactively working with the FDA on this recall and is notifying distributors and direct customers via email to ensure the safe return of all recalled products, reflecting the company's commitment to compliance and safety.
- Customer Support: The company provides detailed recall information and support channels, including phone and email, ensuring customers can smoothly return products and address related issues, highlighting Neogen's focus on customer service.
See More
Neogen (NEOG) Q2 2026 Earnings Call Transcript
See More
WD-40 Co Reports Q1 Earnings Miss, Shares Drop 9.1%
- Earnings Decline: WD-40 Co reported Q1 earnings of $1.28 per share, missing the analyst consensus of $1.36, indicating pressure on profitability that could undermine investor confidence.
- Sales Miss: The company's quarterly sales of $154.423 million fell short of the expected $155.085 million, reflecting weak market demand that may lead to further performance declines.
- Stock Reaction: Following the disappointing results, WD-40 shares dropped 9.1% to $185.00 in pre-market trading, highlighting market concerns regarding the company's financial health.
- Industry Impact: The poor performance of WD-40 may trigger a ripple effect across the industry, prompting investors to reassess the financial health of similar companies, potentially leading to a broader market sentiment downturn.
See More
Neogen Corp (NEOG) Stock Surpasses Analyst Target Price at $9.70
- Price Breakthrough: Neogen Corp's stock has surpassed the average analyst 12-month target price of $8.17, currently trading at $9.70, indicating market confidence in the company's future and potentially prompting analysts to reassess their target prices.
- Analyst Reactions: Among analysts covered by Zacks, target prices range from $6.50 to $10.00, with a standard deviation of $1.755, highlighting differing expectations for Neogen and suggesting investors should proceed with caution.
- Investor Signal: The stock's rise above the average target price provides investors with a signal to reassess Neogen, prompting them to consider whether to hold or take profits, reflecting market scrutiny of the company's valuation.
- Market Dynamics: The varying target prices among analysts reflect differing views on Neogen's growth potential, urging investors to monitor fundamental business developments to make informed investment decisions.
See More
Neogen Corporation Initiates Nationwide Recall of HYCOAT Product
- Product Recall: Neogen Corporation has initiated a voluntary recall of all unexpired lots of its HYCOAT Hyaluronate Sodium Sterile Solution due to identified microbial contamination in certain batches, impacting its use for topical wound management in dogs, cats, and horses.
- Adverse Event Reports: The company received several adverse event reports following intra-articular injections in horses, a use inconsistent with the product's labeling, although no adverse events were reported when used as directed, highlighting the risks associated with improper use.
- Infection Risk Warning: Neogen warned that affected products should no longer be considered sterile, posing an infection risk particularly if injected into joints or used topically in surgical wounds, burns, ulcers, and autograft procedures.
- Stock Price Reaction: According to Benzinga Pro data, NEOG stock fell 2.80% to $10.06 in the last check on Thursday, reflecting the market's negative response to the recall event.
See More
Neogen Voluntarily Recalls HYCOAT Product Due to Contamination
- Product Recall: Neogen Corporation is voluntarily recalling all lots of Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution due to microbial contamination in certain 10 mL/50 mg vials, which poses a risk of infection in animals and could damage the company's reputation.
- Adverse Event Reports: The company has received multiple reports of adverse events in horses following intraarticular injections, although no issues have been reported when used as intended, highlighting the risks associated with improper use of the product.
- Collaboration with FDA: Neogen is proactively working with the FDA to investigate the issue and is notifying distributors and customers to ensure a smooth recall process, aiming to mitigate potential legal and financial risks.
- Customer Support: The company is providing a customer support hotline to assist with recall procedures, demonstrating its commitment to customer safety, which may also impact future sales and market trust.
See More
Neogen Voluntarily Recalls HYCOAT Product Due to Contamination
- Product Recall: Neogen Corporation is voluntarily recalling all lots of Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution due to microbial contamination found in certain batches, involving both 2mL/20mg and 10mL/50mg vials, demonstrating the company's commitment to product safety.
- Adverse Event Reports: Following intraarticular injections in horses, Neogen received multiple reports of adverse events, although no issues were reported when used as intended, indicating potential serious consequences from improper use that could impact the company's reputation.
- Collaboration with FDA: Neogen is proactively working with the FDA on this recall and is notifying distributors and direct customers via email to ensure the safe return of all recalled products, reflecting the company's commitment to compliance and safety.
- Customer Support: The company provides detailed recall information and support channels, including phone and email, ensuring customers can smoothly return products and address related issues, highlighting Neogen's focus on customer service.
See More
Neogen (NEOG) Q2 2026 Earnings Call Transcript
See More
WD-40 Co Reports Q1 Earnings Miss, Shares Drop 9.1%
- Earnings Decline: WD-40 Co reported Q1 earnings of $1.28 per share, missing the analyst consensus of $1.36, indicating pressure on profitability that could undermine investor confidence.
- Sales Miss: The company's quarterly sales of $154.423 million fell short of the expected $155.085 million, reflecting weak market demand that may lead to further performance declines.
- Stock Reaction: Following the disappointing results, WD-40 shares dropped 9.1% to $185.00 in pre-market trading, highlighting market concerns regarding the company's financial health.
- Industry Impact: The poor performance of WD-40 may trigger a ripple effect across the industry, prompting investors to reassess the financial health of similar companies, potentially leading to a broader market sentiment downturn.
See More
Neogen Corp (NEOG) Stock Surpasses Analyst Target Price at $9.70
- Price Breakthrough: Neogen Corp's stock has surpassed the average analyst 12-month target price of $8.17, currently trading at $9.70, indicating market confidence in the company's future and potentially prompting analysts to reassess their target prices.
- Analyst Reactions: Among analysts covered by Zacks, target prices range from $6.50 to $10.00, with a standard deviation of $1.755, highlighting differing expectations for Neogen and suggesting investors should proceed with caution.
- Investor Signal: The stock's rise above the average target price provides investors with a signal to reassess Neogen, prompting them to consider whether to hold or take profits, reflecting market scrutiny of the company's valuation.
- Market Dynamics: The varying target prices among analysts reflect differing views on Neogen's growth potential, urging investors to monitor fundamental business developments to make informed investment decisions.
See More
